Vicarious Surgical Inc.
No enriched coverage for $RBOT in the last 7 days.
No SEC Form 4 filings for $RBOT in the last 30 days.
See all $RBOT insider activity →Vicarious Surgical, a robot developer that raised over $425 million including from Bill Gates and was valued at about $1.1 billion in its 2021 SPAC merger, said shareholders approved a wind-down and liquidation via an assignment for the benefit of creditors. The company cited delays, cash burn, canceled trials, and failed FDA authorization, and it moved to OTC after an NYSE delisting notice.
Vicarious Surgical Inc. (RBOT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001812173 0001812173 2026-07-21 2026-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor
Vicarious Surgical’s board recommended shareholders approve a plan to dissolve the company and liquidate assets through an insolvency procedure, citing recurring operating losses, negative cash flows, and insufficient cash to continue as a going concern. A July 21 stockholder vote is planned. Cash was about $3.7M as of March 31. Shares were delisted from the NYSE earlier this year.
Recent RBOT coverage spans corporate actions, financial news and mergers & acquisitions.
Wind-down and creditor-trust liquidation materially increases downside risk and likely eliminates equity recovery prospects.
The filing signals a creditor-led asset transfer and likely wind-down, which is typically highly negative for equity holders and can drive sharp de-rating or illiquidity.
Wind-down and insolvency recommendation materially increases downside risk and likely accelerates liquidation over coming weeks.
CFO transition can affect near-term finance leadership, reporting cadence, and investor confidence, but no replacement or financial guidance is provided here.
Vicarious Surgical reported a narrower-than-expected loss in Q2 2025, indicating potential operational improvements and positive investor sentiment.
alphai scores every news story that mentions RBOT with an AI model for sentiment and relevance, and aggregates insider trades from Vicarious Surgical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vicarious Surgical, a robot developer that raised over $425 million including from Bill Gates and was valued at about $1.1 billion in its 2021 SPAC merger, said shareholders approved a wind-down and liquidation via an assignment for the benefit of creditors. The company cited delays, cash burn, canceled trials, and failed FDA authorization, and it moved to OTC after an NYSE delisting notice.
3 min readVicarious Surgical Inc. (RBOT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001812173 0001812173 2026-07-21 2026-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor
4 min readVicarious Surgical’s board recommended shareholders approve a plan to dissolve the company and liquidate assets through an insolvency procedure, citing recurring operating losses, negative cash flows, and insufficient cash to continue as a going concern. A July 21 stockholder vote is planned. Cash was about $3.7M as of March 31. Shares were delisted from the NYSE earlier this year.
4 min readVicarious Surgical Inc. (RBOT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001812173 0001812173 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readVicarious Surgical ( NYSE:RBOT ) , a developer focused on next-generation robotic technology for minimally invasive surgery, released its second quarter 2025 financial results on August 12, 2025. The standout news: the company posted a narrower non-GAAP net loss than analysts anticipated, with an ...
4 min readDesigned for investors, board members, and CEOs, the latest PatentVest Pulse reveals who's actually leading and why in one of the most underpenetrated markets in medtech Designed for investors, board members, and CEOs, the latest PatentVest Pulse reveals who's actually leading and why in one of ...
3 min readRUTHERFORD, N.J., May 28, 2025 ( GLOBE NEWSWIRE ) -- Glucotrack, Inc. GCTK, a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E.
2 min read
